Table 3.
Blinatumomab treatment outcome and MRD response.
| Number N = 13 |
MRD-FC Prior 1st Cycle | MRD-FC Post 1st Cycle | MRD-FC Post 2nd Cycle | Responder (R) vs. Nonresponder (NR) | Treatment Post Blinatumomab | Follow-Up Duration (Months) |
|---|---|---|---|---|---|---|
| 1 | 32.7% | 0.36% | <0.01% | R | MUD HSCT | 47 |
| 2 | 0.1% | <0.01% | R | MSD HSCT | 40 | |
| 3 | 0.1% | <0.01% | R | MSD HSCT | 38 | |
| 4 * | 0.01% | <0.01% | - | R | MUD HSCT | 39 |
| 5 | 55% | 97% | NR | Palliative care | 1 DEAD | |
| 6 | 0.03% | <0.01% | <0.01% | R | MUD HSCT | 32 |
| 7 | 37% | 28% | NR | Clofarabine | 3 DEAD | |
| 8 | 0.03% | <0.01% | <0.01% | R | MSD HSCT | 26 |
| 9 | 0.2% | <0.01% | R | haploidentical HSCT | 23 | |
| 10 | 0.15% | <0.01% | <0.01% | R | haploidentical HSCT | 22 |
| 11 | 0.01% | <0.01% | <0.01% | R | MUD HSCT | 14 |
| 12 | 0.2% | <0.01% | R | MUD HSCT | 25 | |
| 13 | 0.15% | <0.01% | R | MUD HSCT | 2 |
MSD, matched sibling donor; MUD, matched unrelated donor; HSCT, hematopoietic stem cell transplantation; R, responder to blinatumomab; NR, nonresponder to blinatumomab. * Patient 4 discontinued blinatumomab treatment after 4 days.